Chaires J B
Nucleic Acids Res. 1983 Dec 10;11(23):8485-94. doi: 10.1093/nar/11.23.8485.
The cancer drug daunomycin is an effective inhibitor of the B leads to Z transition in poly d(G-C) in 4 M NaCl. Both the rate and extent of the B leads to Z transition are decreased by the drug, as judged by equilibrium and kinetic studies. Daunomycin can, under some conditions, convert Z form DNA back to B form. Drug binding to poly d(G-C) in 4 M NaCl is slow and highly cooperative, consistent with a role for daunomycin as an allosteric effector on the B leads to Z equilibrium. Since daunomycin binds preferentially to alternating purine-pyrimidine sequences, which are the very sequences capable of undergoing the B leads to Z transition, these effects may be an important part of the mechanism by which the drug inhibits transcription and replication.
抗癌药物柔红霉素是4M氯化钠中聚d(G-C)由B型向Z型转变的有效抑制剂。通过平衡和动力学研究判断,药物降低了B型向Z型转变的速率和程度。在某些条件下,柔红霉素可将Z型DNA转化回B型。柔红霉素在4M氯化钠中与聚d(G-C)的结合缓慢且具有高度协同性,这与柔红霉素作为B型向Z型平衡的变构效应剂的作用一致。由于柔红霉素优先结合交替的嘌呤-嘧啶序列,而这些序列正是能够发生B型向Z型转变的序列,因此这些效应可能是该药物抑制转录和复制机制的重要组成部分。